The association between hyperostosis frontalis interna (HFI), acromegaly and hyperprolactinaemia was investigated. Thirty six acromegalic patients, of whom 19 had hyperprolactinaemia, were compared with 36 randomly-selected, age-sex matched controls. There was a higher prevalence of HFI in the skull X-rays of the acromegalic cohort (P = 0.0002) when compared to the control group. This difference was apparent in both men (P = 0.01) and women (P = 0.01). Acromegalic patients with hyperprolactinaemia also expressed HFI in a higher proportion of individuals than the control group (P = 0.0001). Intra-and interobserver variability was assessed and concordance with 100% and 97% in the moderate and severe HFI sub-groups. The following sub-group analysis was undertaken: acromegalics and those acromegalics with hyperprolactinaemia were compared with the controls and a highly significant distinction was confirmed (P = 0.0007 and P = 0.00001 respectively). A relationship between HFI severity and the patient's age was noted in both male and female acromegalics. Also, the severity of HFI appeared related to disease duration in female acromegalics.
Introduction
Hyperostosis frontalis interna (HFI) is a common, often incidental, finding on a skull X-ray. It is considered to occur more frequently in women with a quoted female:male sex ratio of9:1. It has a peak incidence in the 40-60 year age group, in which group 15-20% of women are reported to have some evidence of HFI.
Despite its frequent occurrence, the exact cause of HFI Our observed female:male ratio in acromegalics with HFI was 1.6:1. There was, in addition, a relationship between the severity of HFI and the patient's age in both male and female acromegalics (Table IV) . This trend was not apparent in the control group. A similar, though less marked, relationship was found between the severity of HFI and the duration of acromegaly, but only in the female acromegalic patients. addition, have some symptomatic significance. The retrospective nature of our study unfortunately precluded accurate recording of key symptoms such as headache. However, the association of headache with HFI is well established in the MSM syndrome. Headache also occurs in 50-87% of acromegalic patients5 and does not appear to correlate with tumour size, hormone levels, suprasellar extension, age, obesity or blood pressure. The persistence of headache after effective treatment of the pituitary adenoma may be due to the presence of HFI. As the headache of HFI is presumed to be due to bone overgrowth of the inner table of the skull, analgesia may potentially be achieved using those diphosphonate derivatives shown to have pain-relieving properties in Paget's disease.
In summary, HFI is strongly associated with acromegaly, both with and without hyperprolactinaemia. Its cause remains unknown but many factors are implicated. The presence of HFI may have symptomatic significance and its presence or absence should be established in all patients with acromegaly and hyperprolactinaemia.
